Literature DB >> 9773980

Two separate NCoR (nuclear receptor corepressor) interaction domains mediate corepressor action on thyroid hormone response elements.

R N Cohen1, F E Wondisford, A N Hollenberg.   

Abstract

The nuclear corepressor (NCoR) binds to the thyroid hormone receptor (TR) in the absence of ligand. NCoR-TR interactions are mediated by two interaction domains in the C-terminal portion of NCoR. Binding of NCoR to TR results in ligand-independent repression on positive thyroid hormone response elements. The interactions between NCoR interaction domains and TR on DNA response elements, however, have not been well characterized. We have found that both interaction domains are capable of binding TR on thyroid hormone response elements. In addition, the NCoR interaction domains interact much more strongly with the TR than those present in the silencing mediator of retinoic acid and TRs (SMRT). Furthermore, deletion of either NCoR interaction domain does not significantly impair ligand-independent effects on positive or negative thyroid hormone response elements. Finally, both NCoR interaction domains appear to preferentially bind TR homodimer over TR-retinoid X receptor heterodimer in electrophoretic mobility shift assays. These data suggest that either NCoR interaction domain is capable of mediating the ligand-independent effects of TR on positive and negative thyroid hormone response elements.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9773980     DOI: 10.1210/mend.12.10.0188

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  18 in total

1.  Molecular determinants of nuclear receptor-corepressor interaction.

Authors:  V Perissi; L M Staszewski; E M McInerney; R Kurokawa; A Krones; D W Rose; M H Lambert; M V Milburn; C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

2.  Determinants of CoRNR-dependent repression complex assembly on nuclear hormone receptors.

Authors:  X Hu; Y Li; M A Lazar
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II).

Authors:  Y Zhou; W Gross; S H Hong; M L Privalsky
Journal:  Mol Cell Biochem       Date:  2001-04       Impact factor: 3.396

4.  The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT.

Authors:  Xiaolin Li; Donald P McDonnell
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

5.  SMRTε, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors α and β.

Authors:  Brenda J Mengeling; Michael L Goodson; William Bourguet; Martin L Privalsky
Journal:  Mol Cell Endocrinol       Date:  2012-01-12       Impact factor: 4.102

6.  Alternative mRNA splicing of corepressors generates variants that play opposing roles in adipocyte differentiation.

Authors:  Michael L Goodson; Brenda J Mengeling; Brian A Jonas; Martin L Privalsky
Journal:  J Biol Chem       Date:  2011-11-07       Impact factor: 5.157

7.  Heterodimers of retinoic acid receptors and thyroid hormone receptors display unique combinatorial regulatory properties.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Mol Endocrinol       Date:  2005-01-13

8.  Multiple mutations contribute to repression by the v-Erb A oncoprotein.

Authors:  Sangho Lee; Martin L Privalsky
Journal:  Oncogene       Date:  2005-10-13       Impact factor: 9.867

9.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

Authors:  Myles C Hodgson; Howard C Shen; Anthony N Hollenberg; Steven P Balk
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

10.  The nuclear corepressor, NCoR, regulates thyroid hormone action in vivo.

Authors:  Inna Astapova; Larissa J Lee; Crystal Morales; Stefanie Tauber; Martin Bilban; Anthony N Hollenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.